
Experimental drug helps patients lose nearly a quarter of body weight in early trials
Fox News
Novo Nordisk's experimental pill amycretin shows promising results in early trials, with participants losing up to 24.3% of body weight by targeting two hunger hormones.
"Amycretin is the first treatment to harness the two distinct biological pathways stimulated by amylin and GLP-1 in a single molecule." Melissa Rudy is senior health editor and a member of the lifestyle team at Fox News Digital. Story tips can be sent to melissa.rudy@fox.com.
"Amycretin is the first treatment to harness the two distinct biological pathways stimulated by amylin and GLP-1 in a single molecule," Martin Holst Lange, executive vice president and head of development at Novo Nordisk, previously said in a statement sent to Fox News Digital.

Pizza before tomatoes? Ancient Rome's version of America's favorite food looked nothing like today's
Ancient Rome pizza at Hungary restaurant features no tomatoes or mozzarella, using garum fish sauce and olive paste. Neverland Pizzeria's dish is limited-edition.












